Evaluation of lorcainide, a new anti-arrhythmic agent
- PMID: 7302777
Evaluation of lorcainide, a new anti-arrhythmic agent
Abstract
A new anti-arrhythmic agent, lorcainide, has been compared with lignocaine in patients with acute myocardial infarction. Lorcainide has been shown to be as effective as lignocaine in suppressing ventricular ectopy. Lorcainide is unusually free of side-effects and has the great advantage over lignocaine of being effective when given orally.